A Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of Allogeneic iNKT Cell Infusion in Subjects With Advanced Pancreatic Cancer

NCT07055568 · clinicaltrials.gov ↗

NA

Phase

NOT_YET_RECRUITING

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Cancer

Interventions

DRUG: iNKT

Sponsor

Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine